

References for CEQUA[®] (cyclosporine ophthalmic solution) 0.09%

^a**Study design:** Single-arm, open-label study evaluating 60 (46 assessable) patients at 7, 14, and 28 days. The primary endpoint was corneal higher-order aberrations. Exclusion criteria were similar to past studies with the exception that patients switching from another dry eye medication were not excluded.¹

^bThe safety of CEQUA was evaluated in clinical trials that included 769 patients who received at least 1 dose of study treatment.³

^cGrade 0 is no staining and 1 represents minimal staining.

References:

1. Cequa Onset of Action Trial (COAT) presented at: American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting; April 4-8, 2025; Los Angeles, CA.
2. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. *Ophthalmology*. 2019;126(9):1230-1237.
3. CEQUA prescribing information. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2022.

© 2025 Sun Pharmaceutical Industries, Inc. All rights reserved. CEQUA is a registered trademark of Sun Pharmaceutical Industries Limited.

PM-US-CQA-1895 06/2025

